M&A
The $600M Bet: How the Global Race for Weight-Loss Drugs is Rewriting the Rules of Biotech Investing and Tapping into China’s R&D Power
A US biotech’s $600M raise for weight-loss drugs reveals a key strategy: using China for faster, cheaper clinical trials, altering biotech investing.
Goldman Sachs’ Blockbuster Quarter: Decoding the Roar of Investment Banking and What It Signals for the Global Economy
Goldman Sachs’ profits soared 28%, driven by a powerful resurgence in investment banking. Discover what this signals for the economy and stock market.
The Price of Politics: Why Your Next Global Deal Could Come with a Hefty Discount
The Nexperia case in the Netherlands heralds a new era of M&A, where geopolitical risk forces a “political risk discount” on international deals.
Corporate Turmoil, Global Bets, and a Founder’s Fall: Decoding the Week’s Biggest Financial Dramas
A founder’s exit from a $12bn firm, a lottery giant’s US dream, and HSBC’s risky Hong Kong bet. We decode the week’s top financial dramas.